Trials / Terminated
TerminatedNCT00939276
Macular Edema Incidence/Severity Reduction With Nevanac
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 175 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate NEVANAC in patients with diabetic retinopathy who developed macular edema (ME) within 90 days following cataract surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nepafenac ophthalmic suspension, 0.1% (NEVANAC®) | One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery |
| DRUG | Nepafenac ophthalmic suspension vehicle | One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2011-05-01
- Completion
- 2011-08-01
- First posted
- 2009-07-14
- Last updated
- 2012-10-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00939276. Inclusion in this directory is not an endorsement.